Macrocyclic drugs

Scope: non-peptide and small-molecule-like macrocycles

Macrocycles are commonly defined by a ring containing at least 12 atoms, and many occupy chemical space beyond the Rule of Five.^[S4][S5] This article focuses on non-peptide and small-molecule-like macrocycles. For a sponsor commissioning nonclinical work, the main additions to a conventional small-molecule package are environment-dependent conformation and permeability, broad off-target profiling, explicit CYP and transporter work, and tissue-exposure measurements where accumulation is plausible. Peptide cleavage and ADA strategy are covered in the companion cyclic-peptide article.

US regulatory examples

Tacrolimus

Prograf (tacrolimus) received initial US approval in 1994. Its FDA-approved labeling carries a boxed warning for malignancies and serious infections associated with immunosuppression.^[S1] The supplied source verifies those regulatory facts but not the structural and molecular-glue claims in the Japanese text, so those claims are omitted. This example is not presented as a recommendation or a comparison of clinical performance.

Lorlatinib

FDA approved Lorbrena (lorlatinib) on November 2, 2018, for ALK-positive metastatic non-small cell lung cancer.^[S2] The supplied research did not verify the claim that macrocyclization produced particular blood-brain barrier penetration or activity against G1202R, so this article does not repeat it. If either property is part of a new candidate's rationale, it requires a prespecified nonclinical assay and direct exposure or activity data.

Glecaprevir

FDA approved the glecaprevir and pibrentasvir combination Mavyret on August 3, 2017, for adults with chronic hepatitis C virus infection.^[S3] The approval source does not support the Japanese text's claims about binding affinity, resistance barrier, or status as a success example, so they are omitted. A resistance panel for a new antiviral macrocycle should report activity against defined variants without turning that result into a clinical-performance claim.

Small-molecule-like questions that become harder for macrocycles

Environment-dependent conformation and permeability

Large flexible macrocycles are being studied for chameleonic behavior in which conformation and apparent polarity change with environment.^[S6] Do not infer permeability or absorption from one LogP, LogD, or surface-area value. Pair measurements in different media with conformational analysis and orthogonal permeability assays, then compare those results with observed PK. This establishes an empirical relationship for the candidate; it does not validate a universal macrocycle rule or predict human exposure.

Residual flexibility and off-target activity

Treat selectivity as an empirical question. Choose biochemical and cellular counter-screens from the target family, structural alerts, and any activity already observed, and test them at unbound exposure-relevant concentrations. Where binding kinetics matter, measure association and dissociation separately from equilibrium affinity. A cell-free result identifies possible interactions; cellular engagement and functional follow-up determine whether those interactions operate in the tested system.

CYP enzymes, transporters, and tissue accumulation

Plan CYP and transporter studies from the candidate's measured clearance, permeability, and concentration range rather than assuming a class-wide interaction pattern. Distinguish substrate, inhibitor, and inducer questions, and include time dependence where the chemistry or preliminary data justify it. If repeat-dose PK or pathology suggests tissue accumulation, quantify parent and relevant metabolites in the affected tissue and include a recovery phase. These data characterize DDI and accumulation hypotheses; they do not demonstrate a clinical interaction on their own.

A macrocycle-specific extension to the small-molecule package

1. Link conformation to measured permeability

Use more than one permeability environment and record recovery, nonspecific binding, solubility, and transporter effects before ranking compounds. Add conformational analysis where the molecule is flexible enough for environment-dependent behavior to be plausible; computational work on large flexible macrocycles illustrates why solvent-dependent distribution can matter.^[S6] Compare those data with in vivo PK, but describe the result as a candidate-specific correlation rather than "true permeability" or a prediction of human absorption.

2. Separate binding kinetics from cellular engagement

If duration of target binding is part of the candidate rationale, measure association, dissociation, and equilibrium affinity with a qualified method, then test target engagement in intact cells over time. Align those measurements with unbound concentration and the downstream functional endpoint. A PK/PD model can summarize the nonclinical relationship, but it does not by itself determine a clinical dosing interval.

3. Quantify tissue exposure before adding imaging

Define the tissue-exposure question first. Quantify parent and relevant metabolites at pharmacology and pathology timepoints, with matrix-specific validation and stability controls. Add imaging or microdialysis only when regional or unbound exposure is needed for interpretation. A spatial signal is useful only if chemical identity, sensitivity, and resolution are adequate for the decision. Relating local exposure to a finding can support a mechanism; it does not establish what will occur in patients.

4. Integrate off-target, CYP, transporter, and repeat-dose findings

Build the safety panel from observed pharmacology, structural alerts, intended exposure, and preliminary metabolism and transporter data. Define follow-up criteria before screening so that weak, high-concentration signals are not overinterpreted. Integrate confirmed off-target activity with repeat-dose exposure, clinical pathology, and histopathology. Modeling may organize those data for first-in-human planning, but it cannot "secure" a safety margin or ensure that a selected starting dose is safe.

What to confirm with a contract laboratory

Ask how the laboratory will connect conformational and permeability data with observed PK, qualify CYP and transporter assays over the candidate's concentration range, confirm off-target hits in cells, and quantify parent and metabolites in tissues. Require recovery and binding controls, prespecified follow-up thresholds, and a plan for integrating DMPK, pharmacology, and toxicology. Select against the candidate's questions and deliverables; no breadth-of-services claim guarantees development success.